Bp Plc Holds Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bp Plc maintained its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, Holdings Channel reports. The fund owned 10,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Bp Plc’s holdings in Regeneron Pharmaceuticals were worth $4,912,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the stock. Korea Investment CORP boosted its stake in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the period. FNY Managed Accounts LLC acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at about $140,000. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. IFP Advisors Inc boosted its stake in Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 96 shares during the period. Finally, Wendell David Associates Inc. acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $204,000. 66.70% of the stock is owned by hedge funds and other institutional investors.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 469.68 on Wednesday. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55. The stock has a market capitalization of $49.58 billion, a P/E ratio of 56.86 and a beta of 1.66. The firm’s 50-day moving average price is $499.39 and its 200-day moving average price is $422.69.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s revenue was up 21.2% on a year-over-year basis. During the same period last year, the firm earned $2.82 earnings per share. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $14.84 EPS for the current fiscal year.
WARNING: “Bp Plc Holds Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/09/bp-plc-holds-position-in-regeneron-pharmaceuticals-inc-nasdaqregn.html.
REGN has been the subject of several recent analyst reports. Vetr cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 target price for the company. in a research note on Monday, May 15th. Robert W. Baird cut Regeneron Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $408.00 target price for the company. in a research note on Tuesday, August 1st. Zacks Investment Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 4th. Jefferies Group LLC reissued a “hold” rating and set a $357.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 12th. Finally, Credit Suisse Group cut Regeneron Pharmaceuticals to a “hold” rating and set a $485.00 target price for the company. in a research note on Friday, July 14th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $477.91.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $482.55, for a total transaction of $482,550.00. Following the completion of the sale, the director now directly owns 14,000 shares in the company, valued at $6,755,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael S. Brown sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 12th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at $1,350,000. The disclosure for this sale can be found here. Insiders have sold 59,396 shares of company stock valued at $28,484,734 over the last 90 days. Insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.